Matthew Herper

New York

Senior Writer, Medicine and Editorial Director, Events at STAT

Writing and events at STAT. This is biology's century; Every data point has a face. ‘21 Polk Award. Signal: MattHerper.92

Articles

Nuvalent says its ROS1-targeted drug shrank lung tumors in patients who failed other options

3 days ago | statnews.com | Matthew Herper

The biotech firm Nuvalent said Tuesday that new data indicate its targeted drug zidesamtinib could help patients with a rare form of lung cancer that has failed other treatments. For 1% to 2% of patients with non-small cell lung cancer, tumors test positive for alterations in a gene called ROS1. ROS1-positive tumors often respond to one of five targeted therapies on the market, the first of which was approved in 2016 and the most recent of which was approved two weeks ago.
Nuvalent says its ROS1-targeted drug shrank lung tumors in patients who failed other options

3 days ago | flipboard.com | Matthew Herper

2 hours ago"To fix our national pride, the solution is obvious: herpes." That was the pitch made by the charity New Zealand Herpes Foundation last October, when it launched a campaign to make the country the "best place" to have the infection. That campaign has been a roaring success, winning a top prize at …
Disagreements over Duchenne therapy, management style may have led to ouster of key FDA official

1 week ago | statnews.com | Adam Feuerstein |Matthew Herper |Jason Mast |Lizzy Lawrence

The ouster of the Food and Drug Administration’s chief regulator of cell and gene therapies earlier this week came immediately after a disagreement with her boss over the review of a cell therapy for Duchenne muscular dystrophy, STAT has learned. The regulator, Nicole Verdun, had scheduled an advisory committee meeting to review the therapy developed by Capricor Therapeutics.
Disagreements over Duchenne therapy, management style may have led to ouster of key FDA official

1 week ago | flipboard.com | Adam Feuerstein |Matthew Herper |Jason Mast |Lizzy Lawrence

1 hour agoI found the easiest way to delete myself from the internet (and you shouldn't wait to use it, too)If you're looking for a data removal service that can remove you from data broker sales lists and people search websites, Incogni should be on your …5 hours agoYour Apple Watch Is About to Get a Pretty Cool New AbilityApple is gearing up to give your Apple Watch some of your iPhone’s standout features.
Gilead’s CEO on the approval of a powerful new drug to prevent HIV

1 week ago | statnews.com | Matthew Herper

On Wednesday, the Food and Drug Administration approved a new medicine, lenacapavir (brand name: Yeztugo) that could be the closest thing so far to an HIV vaccine: a long-acting antiviral that, given twice a year, can prevent people from contracting the virus. Researchers agree that it could be a game-changer. It is made by Gilead Sciences, whose work in HIV has made it one of the largest biotech companies. This is undoubtedly one of the most important drug approvals this year.
Does the FDA commissioner’s new voucher program open a Pandora’s box?

1 week ago | statnews.com | Matthew Herper

On Tuesday, the Food and Drug Administration said that it would offer U.S. companies that support “U.S. national interests” a voucher to have their new medicine reviewed for approval in one to two months, instead of the 10 months or so products get for a standard review or the six months that are allotted for products for a priority review.
23andMe is won back by Anne Wojcicki and will become a nonprofit

2 weeks ago | statnews.com | Matthew Herper

A nonprofit led by Anne Wojcicki, the co-founder and long-time CEO of genetic data firm 23andMe, won a last-minute bidding war to buy most of the company’s assets for a price of $305 million, the company said in a press release. The news comes less than a month after Regeneron, the biotech giant, had said that it planned to purchase 23andMe out of bankruptcy for $256 million.
The stakes of RFK Jr.’s decision to remake a vaccine panel are life and death

2 weeks ago | statnews.com | Matthew Herper

Public health experts are distraught because Health and Human Services Secretary Robert F. Kennedy Jr. disbanded and reconstituted a federal panel that advises Americans about which vaccines they should receive. Should they be? It is a step many feared Kennedy would take.
A closer look at the new members of the CDC vaccine advisory panel

2 weeks ago | statnews.com | Lizzy Lawrence |Matthew Herper |Isabella Cueto |Elizabeth Cooney |Andrew Joseph |Daniel Payne | +1 more

For more than a half-century, the Centers for Disease Control and Prevention have relied on outside experts to guide the agency’s recommendations on how vaccines should be used to prevent the spread of infectious disease. That task will now fall to a panel that includes several individuals who’ve either been openly critical of vaccines or who have scant infectious disease expertise.
National Resilience, startup hoping to reinvent drug manufacturing, to ‘wind down’ many of its facilities

2 weeks ago | statnews.com | Matthew Herper |Jason Mast |Allison DeAngelis

National Resilience, a startup that has raised over $2 billion by promising to transform drug manufacturing, said Monday that it would “wind down” many of its facilities. But what remains of the firm will seek to raise an additional $250 million from existing investors and continue to build its business and seek more capital. Through a bit of financial engineering, an affiliate of the company that holds leases for six of the company’s manufacturing facilities is filing for bankruptcy.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Coverage map

X (formerly Twitter)

Followers: 111K
Tweets: 113K
DMs Open: Yes

Matthew Herper @matthewherper

7 Jun 25

RT @JasonUkman: Co-founder of @UsAgainstAlz spoke with the NIH director recently and was reassured the agency was committed to continued re…

Matthew Herper @matthewherper

6 Jun 25

RT @Alexander_Tin: Today @US_FDA resumed hiring food investigators, after being stalled for months by @WhiteHouse freeze We're told nearl…

Matthew Herper @matthewherper

6 Jun 25

RT @HelenBranswell: So it looks like #ACIP will be meeting later this month. It will be interesting. 🍿 https://t.co/aHJ0slJ38R

Matthew Herper

Articles

Nuvalent says its ROS1-targeted drug shrank lung tumors in patients who failed other options

Nuvalent says its ROS1-targeted drug shrank lung tumors in patients who failed other options

Disagreements over Duchenne therapy, management style may have led to ouster of key FDA official

Disagreements over Duchenne therapy, management style may have led to ouster of key FDA official

Gilead’s CEO on the approval of a powerful new drug to prevent HIV

Does the FDA commissioner’s new voucher program open a Pandora’s box?

23andMe is won back by Anne Wojcicki and will become a nonprofit

The stakes of RFK Jr.’s decision to remake a vaccine panel are life and death

A closer look at the new members of the CDC vaccine advisory panel

National Resilience, startup hoping to reinvent drug manufacturing, to ‘wind down’ many of its facilities

Contact details

Emails

Socials & Sites

Coverage map

X (formerly Twitter)